Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Firefly Neuroscience Inc (AIFF)

Firefly Neuroscience Inc (AIFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Firefly Neuroscience Appoints Greg Lipschitz as Executive Chairman

Firefly Neuroscience appoints Greg Lipschitz as Executive Chairman, succeeding David Johnson, effective December 3, 2024.Quiver AI SummaryFirefly Neuroscience, Inc. has announced the appointment of Greg...

AIFF : 2.62 (-2.96%)
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

AIFF : 2.62 (-2.96%)
Firefly Neuroscience, Inc. Lists on Nasdaq as "AIFF" and Expands Partnerships to Enhance Brain Health Solutions

Firefly Neuroscience listed on Nasdaq as “AIFF,” focusing on AI-driven solutions for neurological and mental health improvement.Quiver AI SummaryFirefly Neuroscience, Inc. has successfully listed on...

AIFF : 2.62 (-2.96%)
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

AIFF : 2.62 (-2.96%)
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

AIFF : 2.62 (-2.96%)
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AIFF : 2.62 (-2.96%)
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

DRUG : 39.88 (-0.75%)
AIFF : 2.62 (-2.96%)
DRUG.CN : 57.4400 (+6.10%)
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder

AIFF : 2.62 (-2.96%)
Firefly Neuroscience to Participate in Upcoming October Investor Conferences

AIFF : 2.62 (-2.96%)

Barchart Exclusives

Is FedEx Stock a Buy, Sell, or Hold Ahead of Its Freight Spinoff?
Following FedEx’s move to spin off its freight division, does the stock present a compelling buy for investors, or is patience the wiser course? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar